The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a b…
Two biotechs, SIGA and PharmAthene, vying to establish a foothold in the potentially vast biodefense market are in the midst of duking it out in a multibillion dollar legal battle. The crux of the dispute is a smallpox vaccine …
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell — in spite of Crucell’s recent manufacturing troubles.
Continue read…
Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCel…
Among today’s top online stories for investors: The single best biotech opportunity right now; how quantitative easing works; and six stocks bullish insiders are buying like crazy.
Continue reading Daily Blogwa…